The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is the bsAb teclistamab safe and effective in patients with relapsed/refractory MM?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Saad Z. Usmani, Levine Cancer Institute, Charlotte, US. We asked, Is the bispecific antibody teclistamab safe and effective in patients with relapsed/refractory multiple myeloma (MM)?

In this video, Usmani shares the updated phase I results of teclistamab, a bispecific B-cell maturation antigen x CD3 antibody, in patients with relapsed/refractory MM.

 

Share: